Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AORT 
Artivion Inc (AORT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: AORT (4-star) is a SELL. SELL since 1 days. Simulated Profits (39.36%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $42.4
1 Year Target Price $42.4
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 72.78% | Avg. Invested days 52 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.92B USD | Price to earnings Ratio - | 1Y Target Price 42.4 |
Price to earnings Ratio - | 1Y Target Price 42.4 | ||
Volume (30-day avg) 6 | Beta 1.7 | 52 Weeks Range 21.97 - 45.07 | Updated Date 09/15/2025 |
52 Weeks Range 21.97 - 45.07 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.43% | Operating Margin (TTM) 9.72% |
Management Effectiveness
Return on Assets (TTM) 1.7% | Return on Equity (TTM) -5.02% |
Valuation
Trailing PE - | Forward PE 53.19 | Enterprise Value 2130639880 | Price to Sales(TTM) 4.74 |
Enterprise Value 2130639880 | Price to Sales(TTM) 4.74 | ||
Enterprise Value to Revenue 5.26 | Enterprise Value to EBITDA 53.55 | Shares Outstanding 47183700 | Shares Floating 41609852 |
Shares Outstanding 47183700 | Shares Floating 41609852 | ||
Percent Insiders 4.5 | Percent Institutions 89.88 |
Upturn AI SWOT
Artivion Inc
Company Overview
History and Background
Artivion, Inc., formerly CryoLife, Inc., was founded in 1984. Initially focused on cryopreserved human tissues, it has evolved to offer a range of cardiovascular and surgical solutions. Key milestones include expanding its product portfolio through acquisitions and internal development, and focusing on innovative technologies in cardiac and vascular surgery.
Core Business Areas
- Aortic: This segment offers products for the repair and replacement of the aorta, including surgical grafts and stent grafts.
- Cardiac Surgery: This segment includes products used in cardiac valve repair and replacement, as well as other cardiac surgical procedures.
- Perfusion: This segment focuses on products used in extracorporeal circulation, such as oxygenators and blood management devices.
- Surgical Sealants: Offers bioadhesive products such as PerClot used to control bleeding.
Leadership and Structure
Artivion is led by Pat Mackin, Chairman, President, and Chief Executive Officer. The company has a traditional corporate structure with a board of directors overseeing the executive management team, who are responsible for the day-to-day operations and strategic direction of the business.
Top Products and Market Share
Key Offerings
- EACTS Graft: Aortic grafts used in open surgical repair of the aorta. No reliable overall market share data available publicly. Competitors include Medtronic (MDT) and Terumo (TRUMO).
- On-X Valves: Mechanical heart valves for aortic and mitral valve replacement. Market share varies by region, but they are a recognized player in the mechanical valve market. Revenue is significant, detailed breakdown not public. Competitors include Abbott (ABT) and Edwards Lifesciences (EW).
- PerClot: Absorbable hemostat used in surgical procedures to control bleeding. PerClot is a significant contributor to the company's surgical sealant revenue. Competitors include Baxter International (BAX) and Ethicon (JNJ).
Market Dynamics
Industry Overview
The cardiovascular and surgical device market is characterized by technological innovation, regulatory scrutiny, and growing demand due to aging populations and increased prevalence of cardiovascular diseases.
Positioning
Artivion is positioned as a specialty player focused on niche segments within the cardiovascular and surgical markets. Its competitive advantages include a specialized product portfolio and established relationships with surgeons.
Total Addressable Market (TAM)
The global cardiovascular device market is estimated to be worth hundreds of billions of dollars. Artivion is focused on a subset of this market with a TAM estimated to be in the billions. The company is positioned to grow through continued innovation and market penetration.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Strong relationships with surgeons
- Focus on innovation
- Established market presence in specific segments
Weaknesses
- Smaller scale compared to larger competitors
- Concentration risk in certain product lines
- Dependence on regulatory approvals
- Limited brand recognition compared to larger players
Opportunities
- Expanding product portfolio through internal development and acquisitions
- Entering new geographic markets
- Leveraging technological advancements in minimally invasive surgery
- Addressing unmet clinical needs in cardiovascular and surgical care
Threats
- Intense competition from larger players
- Pricing pressure from healthcare providers
- Regulatory changes impacting product approvals
- Economic downturns affecting hospital spending
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Edwards Lifesciences (EW)
- Abbott (ABT)
- Terumo (TRUMO)
- Baxter International (BAX)
- Johnson & Johnson (JNJ)
Competitive Landscape
Artivion faces significant competition from larger, more diversified medical device companies. It competes by focusing on niche segments, offering specialized products, and building strong relationships with surgeons.
Major Acquisitions
Ascyrus Medical
- Year: 2021
- Acquisition Price (USD millions): 190
- Strategic Rationale: Expanded aortic product offerings to include Ascyrus Medical Dissection Stent (AMDS), further enhancing Artivionu2019s position in the aortic repair market.
Growth Trajectory and Initiatives
Historical Growth: Artivion has experienced growth through both organic sales increases and strategic acquisitions.
Future Projections: Future growth projections are reliant on financial releases and analyst forecasts. These should be retrieved live from a financial data API.
Recent Initiatives: Recent initiatives include expanding its product offerings through R&D and acquiring companies with complementary technologies.
Summary
Artivion is a specialty cardiovascular and surgical device company with a focused product portfolio and strong surgeon relationships. The company's growth is driven by innovation and strategic acquisitions. Competition from larger players and regulatory challenges remain key risks to consider. Despite challenges, Artivion shows promise through continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
- Company Website
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artivion Inc
Exchange NYSE | Headquaters Kennesaw, GA, United States | ||
IPO Launch date 1993-02-12 | Chairman, President & CEO Mr. James Patrick Mackin | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1600 | Website https://artivion.com |
Full time employees 1600 | Website https://artivion.com | ||
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.